Erratum: Association between bleeding events and in-hospital mortality after percutaneous coronary intervention (JAMA - Journal of the American Medical Association (2013) 309, 10 (1022-1029) DOI:10.1001/jama.2013.1556);Association between bleeding events and in-hospital mortality after percutaneous coronary intervention

JAMA

Volumn 309, Issue 10, 2013, Pages 1022-1029

  Chhatriwalla, Adnan K ^b,c   Amin, Amit P ^d   Kennedy, Kevin F ^a   House, John A ^a   Cohen, David J ^b,c   Rao, Sunil V ^e   Messenger, John C ^f   Marso, Steven P ^b,c  

^a Department of Biostatistics ^*  (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HUMAN; INTRAPROCEDURAL BLEEDING; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES; URINARY TRACT HEMORRHAGE; VASCULAR ACCESS;

EID: 84874921582     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.65529     Document Type: Erratum

References (33)

1. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;53(12):1021-1030.
2. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition vs heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol. 2004;44(9):1792-1800. (Pubitemid 39424077)
3. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49(12):1362-1368. (Pubitemid 46476844)
4. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935. (Pubitemid 37214804)
5. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009;2(3):222-229.
6. Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303(21):2156-2164.
7. Brueck M, Bandorski D, Kramer W, Wieczorek M, Holtgen R, Tillmanns H. A randomized comparison of transradial vs transfemoral approach for coronary angiography and angioplasty. J Am Coll Cardiol. 2009;2(11):1047-1054.
8. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial vs femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J. 2009;157(1):132-140.
9. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patientswith acute coronary syndromes. N Engl J Med. 2006;355(21):2203-2216. (Pubitemid 44791162)
10. Sanborn TA, Ebrahimi R, Manoukian SV, et al. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circ Cardiovasc Interv. 2010;3(1):57-62.
11. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121(1):43-51.
12. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782. (Pubitemid 44268228)
13. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarctionwith the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30(12):1457-1466.
14. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200-1206. (Pubitemid 41505393)
15. Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011;58(17):1750-1756.
16. AHA Hospital Statistics: 2011 Edition. Chicago, IL: American Hospital Association; 2010.
17. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37(8):2240-2245.
18. Weintraub WS, McKay CR, Riner RN, et al American College of Cardiology Database Committee. The American College of Cardiology National Database: progress and challenges. J Am Coll Cardiol. 1997;29(2):459-465. (Pubitemid 27059982)
19. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010;55(18):1923-1932.
20. Austin PC. Optimal caliper widths for propensityscore matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150-161.
21. Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202-1217.
22. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
23. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29(6):661-677.
24. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control. 2007;18(5):571-579. (Pubitemid 46684817)
25. Bender R, Kuss O, Hildebrandt M, Gehrmann U. Estimating adjusted NNT measures in logistic regression analysis. Stat Med. 2007;26(30):5586-5595. (Pubitemid 351193583)
26. Bender R, Vervolgyi V. Estimating adjusted NNTs in randomised controlled trials with binary outcomes: a simulation study. Contemp Clin Trials. 2010;31(5):498-505.
27. Aronow HD, Peyser PA, Eagle KA, et al. Predictors of length of stay after coronary stenting. Am Heart J. 2001;142(5):799-805. (Pubitemid 33016196)
28. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition vs heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52(22):1758-1768.
29. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690-697. (Pubitemid 351221218)
30. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591-602.
31. Lindsey JB, Marso SP, Pencina M, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol. 2009;2(11):1074-1082.
32. Mehran R, Stone GW. New paradigms of care for STEMI focusing on mortality and attributable death analysis: what do device and drug trials teach us? Eur Heart J Suppl. 2009;11(suppl C):C4-C8.
33. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. J Am Coll Cardiol. 2011;4(2):191-197.